A Review of the Treatment for Multiple Myeloma
A panel of experts lead by Dr. Keith Stewart, MB, ChB, discuss the current treatment landscape of multiple myeloma.
Tap into peer-to-peer dialogues covering different therapeutic areas in easy to digest videos, featuring managed care thought leaders.
October 17, 2019 –
Sundar Jagannath, MD, shares his approach to choosing the best treatment plan for patients based on genetic risk in multiple myeloma.
October 17, 2019 –
The key opinion leaders discuss the need for transparency between the National Comprehensive Cancer Network (NCCN) guidelines, payer preference, and real-world patient needs in multiple myeloma.
October 11, 2019 –
The influence of patient cost on choosing an outpatient versus inpatient treatment option are explored in the management of multiple myeloma.
October 11, 2019 –
Sundar Jagannath, MD, emphasizes an individualized treatment approach for relapsed/refractory multiple myeloma.
October 07, 2019 –
Panelists discuss the reimbursement of subcutaneous versus intravenous (IV) dosing and the implications for patients with multiple myeloma.
October 07, 2019 –
A discussion of the Oncology Care Model (OCM) goals to ensure better outcomes for patients with multiple myeloma leads to better cost savings.
September 27, 2019 –
A review of the potential impact of the Oncology Care Model (OCM) on the treatment of multiple myeloma.
September 27, 2019 –
The panel discusses the future of 4-drug combinations for the treatment of multiple myeloma, including the GRIFFIN trial.
September 20, 2019 –
Experts delve into evolving standards of care for patients who are not eligible for transplant in multiple myeloma treatment and discuss the outcomes of the MAIA trial.
September 20, 2019 –
A discussion on the goal of minimal residual disease (MRD) negativity and when is it appropriate to continue or discontinue treatment.
